MedTrace Logo

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

NCT04952467 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-01-14

No results posted yet for this study

Summary

This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-XEN1101 in healthy adult male subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

14C-XEN1101

Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101

Sponsors & Collaborators

Principal Investigators

  • Study Director · Xenon Pharmaceuticals Inc.

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2021-10-04
Completion
2021-10-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952467 on ClinicalTrials.gov